

**INFORMATION ABOUT CONCURRENT USE OF CALCIUM/MAGNESIUM WITH  
Eloxatin® (Oxaliplatin Injection)  
From A Recent Unplanned Interim Analysis of Data from a Phase IV Study (CONcePT)**

An unplanned interim analysis of data from a Phase IV study\* by the Data Monitoring Committee indicated that calcium/magnesium (Ca/Mg) infusions, administered to reduce or prevent oxaliplatin-associated neurological adverse events, may be associated with a reduced response rate to FOLFOX/Bevacizumab treatment in the pooled population of patients receiving either the conventional or the intermittent schedule of Oxaliplatin. Sanofi-aventis closed the study and intends to promptly collect and analyze the study data and to present the findings when the analysis is complete.

Pending more definitive information from this study, health care providers should weigh the perceived beneficial effect on neuropathy of initiating or continuing Ca/Mg infusions in patients on Oxaliplatin against the possibility of diminished benefit of chemotherapy.

If you have any questions, please contact Medical Information Services at: [1-800-633-1610](tel:1-800-633-1610)  
[Option 1](#)

\* CONCEPT - A Phase IV, Randomized, Prospective, Multicenter comparison of an Intermittent Schedule Of Oxaliplatin (IO) combined with 5-Fluorouracil/Leucovorin (FOLFOX) / Bevacizumab Versus the Conventional (CO) Mode of Administration of FOLFOX/Bevacizumab PLUS Neuroprophylaxis With Calcium/Magnesium for the Optimization of First-Line Therapy of Metastatic Colorectal Cancer. Available at: <http://www.clinicaltrials.gov/ct/show/NCT00129870?order=2>